Меню
Идёт набор NCT05527795

Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma

— Наблюдательное Melanoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Frequency and duration of response to adjuvant immunotherapy according to clinical features, Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features, Duration of relapse-free survival according to clinical features, Duration of overall survival according to clinical features.
Кому может быть актуально
Состояния в реестре: Melanoma. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Франция
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

Surgical excision is the treatment of choice for stage II, III and resectable stage IV melanoma and is curative in most cases. Given the recent success of immunotherapy for the treatment of patients with advanced metastatic melanoma, the use of immunotherapy has been evaluated in the adjuvant setting for patients at high risk of recurrence. In this context, Nivolumab prolonged Recurrence-Free Survival (RFS) while reducing toxicity compared with Ipilimumab in a phase III clinical trial, and was subsequently FDA-approved in December 2017 for adjuvant treatment of locally advanced melanoma with metastatic lymph node involvement after resection of cutaneous lesions. While a fraction of patients benefit from adjuvant PD-1 immunotherapy, approximately 40% of patients are still relapsing despite this adjuvant treatment, without being able to identify them early and with poor understanding of resistance mechanisms. Additionally, about 15% of the patients will develop serious adverse effects driven by immunotherapy and often discontinuing or even contraindicating the onset of subsequent treatments, hence affecting global patients care. It is therefore of prime importance to identify clinical features able to predict response and toxicities to adjuvant immunotherapy in melanoma.

Вмешательства

  • Другое Frequency and duration of response to adjuvant immunotherapy according to clinical features
    * Frequency of relapse to adjuvant immunotherapy according to clinical features * Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features
  • Другое Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features
    Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
  • Другое Duration of relapse-free survival according to clinical features
    Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
  • Другое Duration of overall survival according to clinical features
    Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
  • Другое Overall response rate
    Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
  • Другое Frequency of adverse events according to clinical features
    Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features

Первичные конечные точки

  • Duration of response to adjuvant immunotherapy according to clinical features. [Срок оценки: 1 year]

Критерии участия

Критерии включения

  • Patients diagnosed with stage II, III or IV (resected) melanoma
  • Treated by surgery and adjuvant immunotherapy between January 1st of 2019 and January 1st of 2029
  • Gave informed consent to allow the use of biological samples for research purpose
  • Has read the information sheet regarding this study
  • With tumor samples available at the biobank center

Критерии исключения

  • Patients under 18 years old
  • Patients placed under the judicial protection
  • Opposed to this study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Дизайн исследования

Модель наблюдения
Другое

Центры проведения

Франция · 1 центр
  • Centre Hospitalier Lyon Sud — Pierre-Bénite

Идентификаторы

NCT: NCT05527795 · 616

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗